Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

BACKGROUND: The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors reduce pancreatic cancer stem cells (pCSC), stroma and Hh signalling. METHODS: Patients with previously untreated metastatic PDA were treated...

Descripción completa

Detalles Bibliográficos
Autores principales: De Jesus-Acosta, Ana, Sugar, Elizabeth A., O’Dwyer, Peter J., Ramanathan, Ramesh K., Von Hoff, Daniel D., Rasheed, Zeshaan, Zheng, Lei, Begum, Asma, Anders, Robert, Maitra, Anirban, McAllister, Florencia, Rajeshkumar, N. V., Yabuuchi, Shinichi, de Wilde, Roeland F., Batukbhai, Bhavina, Sahin, Ismet, Laheru, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029016/
https://www.ncbi.nlm.nih.gov/pubmed/31857726
http://dx.doi.org/10.1038/s41416-019-0683-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029016/
https://www.ncbi.nlm.nih.gov/pubmed/31857726
http://dx.doi.org/10.1038/s41416-019-0683-3

Ejemplares similares